On the recordSeptember 14, 2016
I am particularly concerned--and I am sure my colleagues have received all sorts of correspondence on what is happening with drug manufacturers--the recent EpiPen situation, where you have a drug that really has not changed much in years, as far as its composition, and, yet, we have seen a 400-percent cost increase by the drug company.
Source
congress.gov




